Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays
Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Institución: | Universitat de Lleida (UdL) |
| Repositorio: | Repositori Obert UdL |
| OAI Identifier: | oai:repositori.udl.cat:10459.1/469733 |
| Acceso en línea: | https://doi.org/10.1002/alz.71192 https://hdl.handle.net/10459.1/469733 |
| Access Level: | acceso abierto |
| Palabra clave: | Alzheimer's disease Automated cerebrospinal fluid assays Cerebrospinal fluid Dementia Mild cognitive dementia Prediction |
| id |
ES_e2fadc1f71c4ca219b6ce5ff363b7ca7 |
|---|---|
| oai_identifier_str |
oai:repositori.udl.cat:10459.1/469733 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assaysvan der Veere, Pietervan Harten, Argondevan Maurik, IngridTeunissen, CharlotteBarkhof, FrederikVos, StephanieFroelich, LutzKornhuber, JohannesWiltfang, JensMaier, WolfgangPeters, OliverRüther, EckartFrisoni, GiovanniSpiru, LuizaFreund-Levi, YvonneWallin, Åsa KHampel, HaraldTsolaki, MagdaKłoszewska, IwonaMecocci, PatriziaVellas, BrunoLovestone, SimonGalluzzi, SamanthaHerukka, Sanna-KaisaSantana, IsabelBaldeiras, I.de Mendonca, AlexandreSilva, DinaChetelat, GaelPoisnel, GéraldineVisser, Pieter JelleJohnson, SterlingStormrud, ErikHansson, OskarPalmqvist, SebastianPiñol Ripoll, GerardBerkhof, Johannesvan der Flier, WiesjeAlzheimer's diseaseAutomated cerebrospinal fluid assaysCerebrospinal fluidDementiaMild cognitive dementiaPredictionAutomated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform. We included 2413 MCI participants (998 [41%] amyloid-positive) from seven observational cohorts. Elecsys was used in 958 (40%) participants. The parameters of the previous ABIDE Cox model were re-estimated. Model discrimination and calibration were evaluated with leave-one-cohort-out cross-validation. During follow-up, 1034 (42%; 585 [58%] amyloid-positive) participants developed dementia. Discrimination was good with Harrell's C of 0.70 (95% confidence interval [CI]: 0.66-0.73). Calibration was good in the total population and amyloid-positive subgroup, with substantial predicted progression risks for all amyloid-positive participants. We refitted the ABIDE model, predicting MCI to dementia progression, with automated CSF measurements. The model was well calibrated in amyloid-positive patients and may support clinical discussions regarding ATTs.Wiley2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1002/alz.71192https://hdl.handle.net/10459.1/469733reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésReproducció del document publicat a https://doi.org/10.1002/alz.71192Alzheimer's and Dementia, 2026, vol. 22, núm. 2, 71192cc-by, (c) Pieter van der Veere et al., 2026Attribution 4.0 Internationalinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:repositori.udl.cat:10459.1/4697332026-06-24T12:42:17Z |
| dc.title.none.fl_str_mv |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| title |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| spellingShingle |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays van der Veere, Pieter Alzheimer's disease Automated cerebrospinal fluid assays Cerebrospinal fluid Dementia Mild cognitive dementia Prediction |
| title_short |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| title_full |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| title_fullStr |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| title_full_unstemmed |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| title_sort |
Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays |
| dc.creator.none.fl_str_mv |
van der Veere, Pieter van Harten, Argonde van Maurik, Ingrid Teunissen, Charlotte Barkhof, Frederik Vos, Stephanie Froelich, Lutz Kornhuber, Johannes Wiltfang, Jens Maier, Wolfgang Peters, Oliver Rüther, Eckart Frisoni, Giovanni Spiru, Luiza Freund-Levi, Yvonne Wallin, Åsa K Hampel, Harald Tsolaki, Magda Kłoszewska, Iwona Mecocci, Patrizia Vellas, Bruno Lovestone, Simon Galluzzi, Samantha Herukka, Sanna-Kaisa Santana, Isabel Baldeiras, I. de Mendonca, Alexandre Silva, Dina Chetelat, Gael Poisnel, Géraldine Visser, Pieter Jelle Johnson, Sterling Stormrud, Erik Hansson, Oskar Palmqvist, Sebastian Piñol Ripoll, Gerard Berkhof, Johannes van der Flier, Wiesje |
| author |
van der Veere, Pieter |
| author_facet |
van der Veere, Pieter van Harten, Argonde van Maurik, Ingrid Teunissen, Charlotte Barkhof, Frederik Vos, Stephanie Froelich, Lutz Kornhuber, Johannes Wiltfang, Jens Maier, Wolfgang Peters, Oliver Rüther, Eckart Frisoni, Giovanni Spiru, Luiza Freund-Levi, Yvonne Wallin, Åsa K Hampel, Harald Tsolaki, Magda Kłoszewska, Iwona Mecocci, Patrizia Vellas, Bruno Lovestone, Simon Galluzzi, Samantha Herukka, Sanna-Kaisa Santana, Isabel Baldeiras, I. de Mendonca, Alexandre Silva, Dina Chetelat, Gael Poisnel, Géraldine Visser, Pieter Jelle Johnson, Sterling Stormrud, Erik Hansson, Oskar Palmqvist, Sebastian Piñol Ripoll, Gerard Berkhof, Johannes van der Flier, Wiesje |
| author_role |
author |
| author2 |
van Harten, Argonde van Maurik, Ingrid Teunissen, Charlotte Barkhof, Frederik Vos, Stephanie Froelich, Lutz Kornhuber, Johannes Wiltfang, Jens Maier, Wolfgang Peters, Oliver Rüther, Eckart Frisoni, Giovanni Spiru, Luiza Freund-Levi, Yvonne Wallin, Åsa K Hampel, Harald Tsolaki, Magda Kłoszewska, Iwona Mecocci, Patrizia Vellas, Bruno Lovestone, Simon Galluzzi, Samantha Herukka, Sanna-Kaisa Santana, Isabel Baldeiras, I. de Mendonca, Alexandre Silva, Dina Chetelat, Gael Poisnel, Géraldine Visser, Pieter Jelle Johnson, Sterling Stormrud, Erik Hansson, Oskar Palmqvist, Sebastian Piñol Ripoll, Gerard Berkhof, Johannes van der Flier, Wiesje |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Alzheimer's disease Automated cerebrospinal fluid assays Cerebrospinal fluid Dementia Mild cognitive dementia Prediction |
| topic |
Alzheimer's disease Automated cerebrospinal fluid assays Cerebrospinal fluid Dementia Mild cognitive dementia Prediction |
| description |
Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform. We included 2413 MCI participants (998 [41%] amyloid-positive) from seven observational cohorts. Elecsys was used in 958 (40%) participants. The parameters of the previous ABIDE Cox model were re-estimated. Model discrimination and calibration were evaluated with leave-one-cohort-out cross-validation. During follow-up, 1034 (42%; 585 [58%] amyloid-positive) participants developed dementia. Discrimination was good with Harrell's C of 0.70 (95% confidence interval [CI]: 0.66-0.73). Calibration was good in the total population and amyloid-positive subgroup, with substantial predicted progression risks for all amyloid-positive participants. We refitted the ABIDE model, predicting MCI to dementia progression, with automated CSF measurements. The model was well calibrated in amyloid-positive patients and may support clinical discussions regarding ATTs. |
| publishDate |
2026 |
| dc.date.none.fl_str_mv |
2026 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://doi.org/10.1002/alz.71192 https://hdl.handle.net/10459.1/469733 |
| url |
https://doi.org/10.1002/alz.71192 https://hdl.handle.net/10459.1/469733 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a https://doi.org/10.1002/alz.71192 Alzheimer's and Dementia, 2026, vol. 22, núm. 2, 71192 |
| dc.rights.none.fl_str_mv |
cc-by, (c) Pieter van der Veere et al., 2026 Attribution 4.0 International info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ |
| rights_invalid_str_mv |
cc-by, (c) Pieter van der Veere et al., 2026 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL) |
| instname_str |
Universitat de Lleida (UdL) |
| reponame_str |
Repositori Obert UdL |
| collection |
Repositori Obert UdL |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869422459976941568 |
| score |
15,812429 |